Pfizer has said it will acquire Colorado-based cancer specialist Array BioPharma for $11.4 billion.
Pfizer has announced that it has entered into a definitive merger agreement under which it will acquire Array – a commercial stage biopharmaceutical company focused on the discovery, development and commercialisation of targeted small molecule medicines for cancer and other diseases with high unmet need.
